FDA Grants Accelerated Approval to GSK’s Neladalkib for Lung Cancer

The FDA approved GSK's neladalkib for lung cancer treatment. GSK acquired the drug through its $10.6B purchase of Nuvalent, completed July 15, adding three lung cancer assets to its portfolio.

Original reporting
Published Nov 17, 2026, 6:35 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 17, 2026, 7:46 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
FDA Grants Accelerated Approval to GSK’s Neladalkib for Lung Cancer — source image
Decision brief

The 30-second read

$GSKBullishMed
01

Why it matters

The FDA’s accelerated approval for neladalkib is a regulatory de-risking event for one of the acquired assets, potentially improving the perceived probability of future approvals and commercialization timelines.

02

Market read

A direct FDA accelerated-approval milestone for a GSK-owned lung cancer therapy is likely to shift expectations for pipeline value and near-term sentiment.

03

What to watch

The article omits efficacy magnitude, safety profile, and the specific accelerated-approval indication, which are key drivers of how durable the valuation impact will be.

Relevance 7/10Novelty 8/10Timing: FDA approval reported Tuesday, likely driving same-day/next-session repricing.

Background

GSK acquired Nuvalent on July 15, adding three lung cancer assets; two were under FDA review at closing and one in Phase 1.

Company-level read

Ticker impact

$GSKBullishMedium confidence
Context

FDA granted accelerated approval to neladalkib, a lung cancer therapy owned by GSK after its Nuvalent acquisition.

Expected impact

Likely positive repricing as investors adjust expectations for neladalkib’s market potential and regulatory momentum.

Evidence & confidence

The article reports a direct FDA approval event for a therapy in GSK’s portfolio, which typically drives biotech/pharma risk-reward re-rating. However, the text provides no efficacy details, label scope, or sales outlook, limiting precision.

Market effects

Supports broader sentiment for oncology drug development and can increase attention on accelerated-approval pathways in lung cancer.

Primarily US regulatory catalyst, with spillover sentiment for global pharma/biotech investors.

US FDA decisions can influence global competitive positioning and partner/investor expectations for lung cancer therapies.

Counterpoint

Accelerated approvals can carry confirmatory-trial risk; without details on confirmatory requirements or label breadth, the market may later discount the initial approval.

Key entities

  • GSK

    Owner of neladalkib after acquiring Nuvalent; subject of the FDA accelerated approval news.

  • neladalkib

    Lung cancer therapy receiving FDA accelerated approval.

  • FDA

    Granted accelerated approval for neladalkib.

  • Nuvalent

    Acquired by GSK; its lung cancer assets formed part of GSK’s pipeline.

Related articles

$GSKMedAI 8/10

GSK’s $10.6bn Nuvalent bet pays off with second lung cancer drug approval

GSK's Nelkarmi (neladalkib) received FDA approval for treating ALK-positive non-small cell lung cancer, the second drug from its $10.6bn Nuvalent acquisition. The approval was based on trial results showing a 49% response rate. GSK expects significant sales, with forecasts predicting $1.2bn by 2032. Roche's Alecensa is a key competitor. Approval hinges on ongoing Phase III trial results.

$GSKMed

GSK Wins Second Lung Cancer Approval of 2026 as FDA Clears Nelkarmi — BigGo Finance

GSK (GSK) received FDA approval for Nelkarmi, a lung cancer drug, based on Phase 1/2 trial data. The drug targets ALK gene mutations and showed activity against brain metastases. GSK acquired Nelkarmi through its $10.6B Nuvalent deal. Analysts project $1B in 2032 sales, with peak sales estimates of $5B-$7B for GSK's lead Nuvalent drugs. The approval is seen as a validation of GSK's oncology portfolio strategy.

$SMMTMedAI 8/10

FDA publishes rejection letter for Summit drug; Nuvalent buyout pays more dividends for GSK

FDA rejected Summit Therapeutics' ivonescimab for lung cancer, citing insufficient benefits. Sellas Life Sciences' cancer vaccine showed 41% reduced death risk in a Phase 3 trial. GSK's Nelkarmi, acquired via Nuvalent buyout, gained FDA approval for lung cancer. AstraZeneca's gefurulimab was approved for myasthenia gravis. Eli Lilly partnered with Stipple Bio for cancer drugs, potentially worth $5.9B. Biogen invested $32M in Trimtech for neurodegenerative disease treatments.

$GSKMed

GSK gets second cancer drug approval from Nuvalent buy

GSK's Nelkarmi (neladalkib) received FDA approval for ALK-positive NSCLC after prior ALK inhibitor treatments. The approval follows GSK's $10.6B acquisition of Nuvalent. Analysts project Nelkarmi, Jideytro, and NVL-330 could generate $5B-$7B in annual sales. Nelkarmi showed a 49% objective response rate in trials. GSK aims to boost revenues to £40B by 2031.

$GSKMed

GSK wins early FDA approval for lung cancer drug Nelkarmi

GSK received early FDA approval for its lung cancer drug Nelkarmi, based on trial data showing meaningful responses in patients with prior ALK inhibitor therapies. The drug demonstrated a 49% response rate in patients with one prior treatment and 32% in those with multiple treatments. GSK noted the approval strengthens its oncology portfolio and addresses unmet needs in ALK-positive lung cancer. As of 1010 GMT, GSK shares were down 0.08% at 1,867.50p.

$GSKHigh

GSK Wins Early FDA Nod for Nelkarmi

GSK (LON: GSK) received accelerated FDA approval for its lung cancer drug Nelkarmi (neladalkib) for ALK-positive non-small cell lung cancer. The approval, based on early trial data, came before the November 27 target date. GSK shares were down 0.16% at 1866p. The drug showed a 49% response rate in patients previously treated with alectinib. GSK also plans to acquire Nuvalent for $10.6bn.